BR112018008870A2 - ?suspensão aquosa e para uso, e, método para preparar uma suspensão? - Google Patents

?suspensão aquosa e para uso, e, método para preparar uma suspensão?

Info

Publication number
BR112018008870A2
BR112018008870A2 BR112018008870-6A BR112018008870A BR112018008870A2 BR 112018008870 A2 BR112018008870 A2 BR 112018008870A2 BR 112018008870 A BR112018008870 A BR 112018008870A BR 112018008870 A2 BR112018008870 A2 BR 112018008870A2
Authority
BR
Brazil
Prior art keywords
suspension
formulations
givinostat
preparing
oral
Prior art date
Application number
BR112018008870-6A
Other languages
English (en)
Other versions
BR112018008870A8 (pt
Inventor
Colombo Giuseppe
Artico Roberta
Mascagni Paolo
Valmen Monzani Maria
Puccianti Silvia
Original Assignee
Italfarmaco S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco S.P.A. filed Critical Italfarmaco S.P.A.
Priority to BR122024001653-2A priority Critical patent/BR122024001653A2/pt
Publication of BR112018008870A2 publication Critical patent/BR112018008870A2/pt
Publication of BR112018008870A8 publication Critical patent/BR112018008870A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)

Abstract

as formulações líquidas orais fisicamente e quimicamente estáveis de givinostat (cloreto de dietil-[6-(4-hidroxicarbamoil-fenilcarbamoiloximetil)-naftalen-2-il-metil]-amônio) são descritas, juntamente com métodos para a preparação da mesmas. tais formulações orais estão na forma de suspensões aquosas e contêm givinostat e/ou sais e/ou derivados farmaceuticamente aceitáveis do mesmo, pelo menos um agente umectante e/ou pelo menos um agente que confere densidade. tais formulações são adequadas para administração oral para ação terapêutica sistêmica.
BR112018008870A 2015-11-03 2016-10-28 ?suspensão aquosa e para uso, e, método para preparar uma suspensão? BR112018008870A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122024001653-2A BR122024001653A2 (pt) 2015-11-03 2016-10-28 Suspensão aquosa e para uso, e, método para preparar uma suspensão

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102015000068150 2015-11-03
ITUB2015A005193A ITUB20155193A1 (it) 2015-11-03 2015-11-03 Sospensioni orali di Givinostat fisicamente e chimicamente stabili
PCT/IB2016/056496 WO2017077436A1 (en) 2015-11-03 2016-10-28 Physically and chemically stable oral suspensions of givinostat

Publications (2)

Publication Number Publication Date
BR112018008870A2 true BR112018008870A2 (pt) 2018-11-06
BR112018008870A8 BR112018008870A8 (pt) 2019-02-26

Family

ID=55410062

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018008870A BR112018008870A8 (pt) 2015-11-03 2016-10-28 ?suspensão aquosa e para uso, e, método para preparar uma suspensão?
BR122024001653-2A BR122024001653A2 (pt) 2015-11-03 2016-10-28 Suspensão aquosa e para uso, e, método para preparar uma suspensão

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122024001653-2A BR122024001653A2 (pt) 2015-11-03 2016-10-28 Suspensão aquosa e para uso, e, método para preparar uma suspensão

Country Status (30)

Country Link
US (1) US10688047B2 (pt)
EP (1) EP3370697B1 (pt)
JP (1) JP6800970B2 (pt)
KR (1) KR102603894B1 (pt)
CN (2) CN108366956B (pt)
AR (1) AR106559A1 (pt)
AU (1) AU2016349169B2 (pt)
BR (2) BR112018008870A8 (pt)
CA (1) CA3002755C (pt)
CL (1) CL2018001151A1 (pt)
CO (1) CO2018003971A2 (pt)
CY (1) CY1124092T1 (pt)
DK (1) DK3370697T3 (pt)
ES (1) ES2870201T3 (pt)
HK (1) HK1254811A1 (pt)
HR (1) HRP20210747T1 (pt)
HU (1) HUE054123T2 (pt)
IL (1) IL258608B (pt)
IT (1) ITUB20155193A1 (pt)
LT (1) LT3370697T (pt)
MX (1) MX2018004505A (pt)
NZ (1) NZ741467A (pt)
PE (1) PE20181369A1 (pt)
PL (1) PL3370697T3 (pt)
PT (1) PT3370697T (pt)
RS (1) RS61694B1 (pt)
RU (1) RU2721396C2 (pt)
SI (1) SI3370697T1 (pt)
TW (1) TWI727983B (pt)
WO (1) WO2017077436A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
WO2022088037A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
CN114306311A (zh) * 2022-01-14 2022-04-12 同济大学 组蛋白去乙酰化酶抑制剂在制备治疗心脏病的药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169150A (en) * 1975-11-12 1979-09-25 Teijin Limited Benzodiazepine derivatives and pharmaceutical compositions containing said derivatives
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US20030157172A1 (en) * 2001-12-20 2003-08-21 Lu Guang Wei Pharmaceutical suspension for oral administration
BR0307575A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Derivados de sulfonila como inibidores de histona desacetilase
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
NZ542445A (en) 2003-04-07 2008-03-28 Pharmacyclics Inc Hydroxamates as therapeutic agents
DE602004004665T2 (de) 2003-08-20 2008-01-03 Pharmacyclics, Inc., Sunnyvale Acetylenderivate als inhibitoren von histondeacetylase
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
AP2283A (en) * 2006-05-19 2011-10-31 Norbrook Lab Ltd Stable aqueous suspension.
KR20090077914A (ko) 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
NZ599558A (en) * 2009-10-30 2014-09-26 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
WO2011113013A2 (en) * 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
EP3858340A1 (en) * 2012-02-03 2021-08-04 Italfarmaco SpA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
WO2014165226A2 (en) * 2013-03-12 2014-10-09 Synedgen, Inc. Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
WO2014159224A1 (en) * 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2015086738A2 (en) 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine

Also Published As

Publication number Publication date
CL2018001151A1 (es) 2018-12-07
AR106559A1 (es) 2018-01-24
PE20181369A1 (es) 2018-08-27
BR122024001653A2 (pt) 2024-03-05
EP3370697A1 (en) 2018-09-12
HK1254811A1 (zh) 2019-07-26
CN108366956B (zh) 2021-09-10
US10688047B2 (en) 2020-06-23
PT3370697T (pt) 2021-04-06
KR20180082468A (ko) 2018-07-18
LT3370697T (lt) 2021-06-10
WO2017077436A1 (en) 2017-05-11
CN108366956A (zh) 2018-08-03
ITUB20155193A1 (it) 2017-05-03
DK3370697T3 (da) 2021-04-26
CN113368044A (zh) 2021-09-10
SI3370697T1 (sl) 2021-04-30
IL258608B (en) 2022-06-01
JP6800970B2 (ja) 2020-12-16
AU2016349169A1 (en) 2018-05-17
TWI727983B (zh) 2021-05-21
PL3370697T3 (pl) 2021-07-12
HUE054123T2 (hu) 2021-08-30
CO2018003971A2 (es) 2018-07-19
KR102603894B1 (ko) 2023-11-20
ES2870201T3 (es) 2021-10-26
CA3002755C (en) 2022-10-18
CY1124092T1 (el) 2022-05-27
US20180311160A1 (en) 2018-11-01
JP2019501116A (ja) 2019-01-17
AU2016349169B2 (en) 2021-11-11
HRP20210747T1 (hr) 2021-06-25
CA3002755A1 (en) 2017-05-11
TW201722401A (zh) 2017-07-01
EP3370697B1 (en) 2021-02-17
RS61694B1 (sr) 2021-05-31
NZ741467A (en) 2021-07-30
RU2721396C2 (ru) 2020-05-19
CN113368044B (zh) 2023-06-02
BR112018008870A8 (pt) 2019-02-26
RU2018120170A (ru) 2019-12-05
IL258608A (en) 2018-06-28
MX2018004505A (es) 2018-09-12
RU2018120170A3 (pt) 2019-12-05

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
CY1124092T1 (el) Φυσικως και χημικως σταθερα απο του στοματος γιβινοστατης
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
MY187047A (en) Selective pyy compounds and uses thereof
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CL2015002387A1 (es) Nuevos derivados de pirazol.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
UY36467A (es) Composición farmacéutica que comprende plasminógeno y usos de este
HRP20200662T1 (hr) Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak
AR112103A1 (es) Compuestos para el tratamiento de tnbc
PE20191241A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CY1123527T1 (el) Αντιφυματικος παραγοντας
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
BR112017025527A2 (pt) preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe.
BR112019001134A2 (pt) uso de lactama e composição farmacêutica
PH12018502139A1 (en) Phosphaplatin liquid formulations
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024001653-2 PROTOCOLO 870240007182 EM 26/01/2024 14:08.

B09A Decision: intention to grant [chapter 9.1 patent gazette]